Open Access
Numéro
OCL
Volume 25, Numéro 4, July-August 2018
Numéro d'article D403
Nombre de pages 4
Section Lipids & Brain IV: Lipids in Alzheimer’s Disease / Lipids & Brain IV : les lipides dans la maladie d’Alzheimer
DOI https://doi.org/10.1051/ocl/2018044
Publié en ligne 29 août 2018
  • Arendt T, Bruckner MK, Mosch B, Losche A. 2010. Selective cell death of hyperploid neurons in Alzheimer’s disease. Am J Pathol 177: 15–20. [CrossRef] [PubMed] [Google Scholar]
  • Binder LI, Frankfurter A, Rebhun LI. 1985. The distribution of tau in the nervous system. J Cell Biol 101: 1371–1378. [Google Scholar]
  • Blacker TS, Mann ZF, Gale JE, et al. 2014. Separating NADH and NADPH fluorescence in live cells and tissues using FLIM. Nature Commun. 5: article number 3936. [CrossRef] [Google Scholar]
  • Bloom GS. 2014. Amyloid-beta and Tau: the Trigger and Bullet in alzheimer disease pathogenesis. JAMA Neurol 71: 505–508. [CrossRef] [PubMed] [Google Scholar]
  • Bomfim TR, Forny-Germano L, Sathler LB, et al. 2012. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease-associated Abeta oligomers. J Clin Invest 122: 1339–1353. [CrossRef] [PubMed] [Google Scholar]
  • Claxton A, Baker LD, Hanson A, et al. 2015. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. J Alzheimer’s Dis 44: 897–906. [CrossRef] [Google Scholar]
  • Craft S, Claxton A, Baker LD, et al. 2017. Effects of regular and long-acting insulin on cognition and Alzheimer’s disease biomarkers: a pilot clinical trial. J Alzheimer’s Dis 57: 1325–1334. [CrossRef] [Google Scholar]
  • de la Monte SM. 2014. Type 3 diabetes is sporadic Alzheimer’s disease: Mini-review. Eur Neuropsychopharm 24: 1954–1960. [CrossRef] [Google Scholar]
  • Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. 1986. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83: 4913–4917. [CrossRef] [PubMed] [Google Scholar]
  • Ittner LM, Ke YD, Delerue F, et al. 2010. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142: 387–397. [CrossRef] [PubMed] [Google Scholar]
  • Kang J, Lemaire HG, Unterbeck A, et al. 1987. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733–736. [CrossRef] [PubMed] [Google Scholar]
  • Kondo J, Honda T, Mori H, et al. 1988. The carboxyl third of tau is tightly bound to paired helical filaments. Neuron 1: 827–834. [CrossRef] [PubMed] [Google Scholar]
  • Kosik KS, Orecchio LD, Binder L, Trojanowski JQ, Lee VMY, Lee G. 1988. Epitopes that span the tau molecule are shared with paired helical filaments. Neuron 1: 817–825. [CrossRef] [PubMed] [Google Scholar]
  • Li L, Cheung T, Chen J, Herrup K. 2011. A comparative study of five mouse models of Alzheimer’s disease: cell cycle events reveal new insights into neurons at risk for death. Int J Alzheimer’s Dis 2011: article ID 171464. [Google Scholar]
  • Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82: 4245–4249. [CrossRef] [PubMed] [Google Scholar]
  • McShea A, Wahl AF, Smith MA. 1999. Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease. Med Hypotheses 52: 525–527. [CrossRef] [PubMed] [Google Scholar]
  • Mosconi L. 2013. Glucose metabolism in normal aging and Alzheimer’s disease: Methodological and physiological considerations for PET studies. Clin Transl Imaging 1: 217–233 [CrossRef] [Google Scholar]
  • Nagy Z, Esiri MM, Cato AM, Smith AD. 1997. Cell cycle markers in the hippocampus in Alzheimer’s disease. Acta Neuropathol 94: 6–15. [CrossRef] [PubMed] [Google Scholar]
  • Norambuena A, Wallrabe H, Cao R, et al. 2018. A novel lysosome-to-mitochondria signaling pathway disrupted by amyloid-β oligomers. EMBO J: in press [Google Scholar]
  • Norambuena A, Wallrabe H, McMahon L, et al. 2017. mTOR and neuronal cell cycle reentry: how impaired brain insulin signaling promotes Alzheimer’s disease. Alzheimers & Dementia 13: 152–167. [CrossRef] [Google Scholar]
  • Pilz GA, Bottes S, Betizeau M, et al. 2018. Live imaging of neurogenesis in the adult mouse hippocampus. Science 359: 658–662. [CrossRef] [Google Scholar]
  • Seward ME, Swanson E, Norambuena A, et al. 2013. Amyloid-beta signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer’s disease. J Cell Sci 126: 1278–1286. [CrossRef] [Google Scholar]
  • Sorrells SF, Paredes MF, Ebrian-Silla AC, et al. 2018. Human hippocampal neurogenesis drops sharply in children to undetectable levels in adults. Nature 555: 377–381. [CrossRef] [PubMed] [Google Scholar]
  • Steen E, Terry BM, Rivera EJ, et al. 2005. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease − is this type 3 diabetes? J Alzheimer’s Dis 7: 63–80. [CrossRef] [Google Scholar]
  • Varvel NH, Bhaskar K, Patil AR, Pimplikar SW, Herrup K, Lamb BT. 2008. Abeta oligomers induce neuronal cell cycle events in Alzheimer’s disease. J Neurosci 28: 10786–10793. [CrossRef] [PubMed] [Google Scholar]
  • Villemagne VL, Burnham S, Bourgeat P, et al. 2013. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12: 357–367. [CrossRef] [PubMed] [Google Scholar]
  • Weingarten MD, Lockwood AH, Hwo S-Y., Kirschner MW. 1975. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 72: 1858–1862. [CrossRef] [PubMed] [Google Scholar]
  • Yang Y, Mufson EJ, Herrup K. 2003. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease. J Neurosci 23: 2557–2563. [CrossRef] [PubMed] [Google Scholar]
  • Zoncu R, Efeyan A, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Rev Mol Cell Biol 12: 21–35. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.